The Clinical Consortium Award provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the FY13 PCRP overarching challenges. Support from this award is directed toward consortium infrastructure needs rather than direct support of the research itself. In accordance with PCRP goals, the conduct of Phase I/II trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer is particularly encouraged.

The principal goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of the disease. To facilitate global investigations, Principal Investigators (PIs) from both U.S. and international institutions are encouraged to apply. Submissions from institutions with enhanced access to patients from disproportionately affected populations are especially encouraged.

New Investigator Fellowships are intended for candidates who at the competition deadline are in the first five years of their career since obtaining the most recent professional research qualification.

The Postdoctoral Fellowship is intended to provide an opportunity for a person with a Ph.D. to obtain further training.  

Two types of grant are available:

Type A: Research Project Grants (2 years)

Applicants may request funds for up to two years. The grant period will be determined by the Foundation and specified in the letters of notification.  Even if the intent is to continue a line of work funded by the Foundation, applications for further support beyond the period of notification will be treated as new applications.

Individuals enrolled in a predoctoral training program are not eligible to apply for a Type A grant.

_______________________________________________________

Type B: Research Project Grants (up to 4 years)

Principal investigators who have been funded by the Foundation for at least four consecutive years in a particular line of research at the time of application, and who can show the need to continue that line of research may apply for support for up to four additional years, through a type B grant. 

Holders of a Type B grant will be expected to submit a satisfactory progress report to secure funding for the 3^rd and 4^th years of the type B grant.  The Foundation must receive the progress report by the September deadline which falls in the 2^nd year of the grant. The Progress Report will be reviewed by the Grants Committee.  

The HDRA supports new ideas based on innovative concepts or methodologies for prostate cancer health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease.

The intent of the PRMRP Discovery Award is to support innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.

The Postdoctoral Training Award supports prostate cancer research training opportunities for recent doctoral graduates. These awards primarily provide salary support for the Principal Investigator (PI); the postdoctoral trainee is considered the PI of the application. The PI must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience.

The Population Science Impact Award mechanism supports high-impact, population science approaches to prostate cancer research. Applications should clearly demonstrate the potential of the study to contribute significantly to the elimination of death from prostate cancer and/or enhancing the well-being of men experiencing the impact of the disease. As such, studies should address one of the PCRP overarching challenges, or, alternatively, justify the study as addressing another critical area in prostate cancer research.

The Exploration - Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis.

Technology Evaluation in the Elderly Network is offering funding for knowledge synthesis projects aimed at improving health care for seriously ill elderly Canadians, their families and caregivers.

The 2013 Knowledge Synthesis Grants will support teams of researchers and knowledge users in producing knowledge syntheses and scoping reviews that will contribute to the use of synthesized evidence in decision-making and practice. Existing knowledge from literature will help guide future research priorities of the Network, and develop publications and tools for Network knowledge translation activities.